PALI Archives - BioTuesdays

Developments

Palisade announces positive PALI-2108 data

Palisade Bio (NASDAQ: PALI) has announced new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor. The company plans to present the results in an oral...

September 17, 2025

Developments

Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD

Palisade Bio (NASDAQ: PALI) has announced receiving a No Objection Letter (NOL) from Health Canada for its clinical trial application to evaluate PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor, in...

September 5, 2025

Developments

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Palisade Bio (NASDAQ:PALI) has announced that it has received a No Objection Letter from Health Canada for its Phase 1 clinical trial of PALI-2108 for the treatment of ulcerative colitis (UC). The orally-administered...

October 10, 2024

Developments

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio (NASDAQ:PALI) entered into a licensing agreement with closely-held Giliant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform...

September 6, 2023

Developments

Palisade Bio flunks Phase 2 study in post-surgical abdominal adhesions

Palisade Bio’s (NASDAQ:PALI) U.S. Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection did not achieve its primary endpoint. Of the patients...

August 9, 2023

Developments

Palisade Bio completes enrollment in dose optimization study

Palisade Bio (NASDAQ:PALI) completed patient enrollment in its dose optimization study of LB1148, a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal...

July 5, 2023

Developments

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

The FDA granted fast tract designation to Palisade Bio’s (NASDAQ:PALI) LB1148 for the acceleration of time to return of bowel function following surgery. By inhibiting the activity of digestive proteases, the company...

November 22, 2022

Executive Moves

JD Finley named interim CEO of Palisade Bio

Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10. In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development...

October 11, 2022

Developments

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With what we believe to be a...

August 17, 2022

Developments

Palisade Bio screens first patient in Phase 3 bowel function trial

Palisade Bio (NASDAQ:PALI) screened the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With the first U.S...

July 27, 2022

Tag - PALI

Palisade announces positive PALI-2108 data

Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio flunks Phase 2 study in post-surgical abdominal adhesions

Palisade Bio completes enrollment in dose optimization study

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

JD Finley named interim CEO of Palisade Bio

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Palisade Bio screens first patient in Phase 3 bowel function trial

Subscribe